Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Yasuhide Ikenaka"'
Autor:
Yasuhide Ikenaka, Hiroshi Fukui, Yusaku Shirai, Mitsuteru Kitade, Akitoshi Douhara, Kosuke Kaji, Kei Moriya, Tadashi Namisaki, Koji Yanase, Hitoshi Yoshiji, Yosuke Aihara, Ryuichi Noguchi, Hideto Kawaratani, Junichi Yoshii
Publikováno v:
Journal of Gastroenterology. 49:481-491
Dipeptidyl peptidase-4 inhibitor (DPP4-I) is clinically used as a new oral antidiabetic agent. Although DPP4 is reportedly associated with the progression of chronic liver diseases, the effect of DPP4-I on liver fibrosis development is still obscure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc159e9972be2d710a88824c39d7b8fd
https://doi.org/10.1007/s00535-013-0783-4
https://doi.org/10.1007/s00535-013-0783-4
Autor:
Yosuke Aihara, Ryuichi Noguchi, Hiroshi Fukui, Kosuke Kaji, Kei Moriya, Yasuhide Ikenaka, Hitoshi Yoshiji, Yusaku Shirai, Akitoshi Douhara, Tadashi Namisaki, Mitsuteru Kitade
Publikováno v:
Hepatology Research. 43:765-774
Aim Both angiotensin-II (AT-II) and aldosterone (Ald) play pivotal roles in the pathogenesis of diseases in several organs including the liver. We previously reported that suppression of AT-II and Ald with angiotensin-converting enzyme inhibitor (ACE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4f5f332b29b79762a3b8c62be345ccb
https://doi.org/10.1111/hepr.12008
https://doi.org/10.1111/hepr.12008
Autor:
Koji Yanase, Junichi Yoshii, Tatsuhiro Tsujimoto, Kosuke Kaji, Yasuhide Ikenaka, Mitsuteru Kitade, Ryuichi Noguchi, Yusaku Shirai, Tadashi Namisaki, Hitoshi Yoshiji, Hiroshi Fukui, Yosuke Aihara, Hideto Kawaratani
Publikováno v:
American Journal of Physiology-Gastrointestinal and Liver Physiology. 300:G1094-G1104
Angiotensin II type I receptor blocker and iron chelator reportedly exert suppressive effects on nonalcoholic steatohepatitis (NASH) progression, including liver fibrosis and hepatocarcinogenesis. The aim of this study was to elucidate the combined e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759694ebd8feebb3b81e720dc9bb549f
https://doi.org/10.1152/ajpgi.00365.2010
https://doi.org/10.1152/ajpgi.00365.2010
Autor:
Kosuke Kaji, Ryuichi Noguchi, Hiroshi Fukui, Hitoshi Yoshiji, Yasuhide Ikenaka, Yosuke Aihara
Publikováno v:
Current Cancer Drug Targets. 11:431-441
Angiogenesis is a complex and critical process essential for supporting the growth of hepatocellular carcinoma (HCC) as well as hepatocarcinogenesis. Recent studies have revealed that renin-angiotensin system (RAS) is involved in many types of cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9f88de05065cd272e5a6e1713c4207
https://doi.org/10.2174/156800911795538084
https://doi.org/10.2174/156800911795538084
Autor:
Hiroshi Fukui, Chie Morioka, Masahisa Toyohara, Ryuichi Noguchi, Hideto Kawaratani, Junichi Yamao, Yusaku Shirai, Kosuke Kaji, Masao Fujimoto, Hitoshi Yoshiji, Masahito Uemura, Tatsuhiro Tsujimoto, Akira Mitoro, Motoyuki Yoshida, Yosuke Aihara, Yasuhide Ikenaka, Masayoshi Sawai
Publikováno v:
Oncology Letters. 2:69-73
The identification of biomarkers of anti-angiogenic therapy that predict clinical benefit is of vital importance. We previously reported that a combination treatment with clinically available safe agents, specifically angiotensin-converting enzyme in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91199d6305378bc9adc84718a9fa0e46
https://doi.org/10.3892/ol.2010.196
https://doi.org/10.3892/ol.2010.196
Autor:
Hiroshi Fukui, Kosuke Kaji, Mitsuteru Kitade, Yasuhide Ikenaka, Tadashi Namisaki, Hideto Kawaratani, Hitoshi Yoshiji, Tatsuhiro Tsujimoto, Masaharu Yamazaki, Ryuichi Noguchi, Yusaku Shirai, Koji Yanase, Junichi Yoshii
Publikováno v:
Hepatology Research. 40:540-549
Aim The renin-angiotensin-aldosterone system (RAAS) has become known as a prerequisite for tumor angiogenesis, including hepatocellular carcinoma (HCC). Although angiotensin II is known to play an important role in tumor growth and angiogenesis, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c6e594c0d025ccad31b1431355a8d43
https://doi.org/10.1111/j.1872-034x.2010.00636.x
https://doi.org/10.1111/j.1872-034x.2010.00636.x
Autor:
Tatsuhiro Tsujimoto, Ryuichi Noguchi, Kosuke Kaji, Yusaku Shirai, Hitoshi Yoshiji, Yasuhide Ikenaka, Tadashi Namisaki, Mitsuteru Kitade, Hiroshi Fukui, Hideto Kawaratani
Publikováno v:
Journal of Gastroenterology. 45:443-450
Insulin resistance (IR) is reportedly involved in the progression of hepatocellular carcinoma (HCC). Because neovascularization plays an important role in HCC, including hepatocarcinogenesis, an angiostatic therapy would be a promising approach for c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d24652b85f19b14f5a8779bbe88033b
https://doi.org/10.1007/s00535-009-0158-z
https://doi.org/10.1007/s00535-009-0158-z
Autor:
Kosuke Kaji, Masao Fujimoto, Yasuhide Ikenaka, Hitoshi Yoshiji, Masahito Uemura, Mitsuteru Kitade, Hideto Kawaratani, Hiroshi Fukui, Tatsuhiro Tsujimoto, Akira Mitoro, Masaharu Yamazaki, Motoyuki Yoshida, Masayoshi Sawai, Masahisa Toyohara, Ryuichi Noguchi, Junichi Yamao
Publikováno v:
Journal of Hepatology. 51:315-321
Background/Aims No chemopreventive agent has been approved against hepatocellular carcinoma (HCC) yet. Since neovascularization plays a pivotal role in HCC, an angiostatic agent is considered as one of the promising approaches. The aim of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5384be2956b2ddb74bde7986032e05ab
https://doi.org/10.1016/j.jhep.2009.04.011
https://doi.org/10.1016/j.jhep.2009.04.011
Publikováno v:
Clinical Rheumatology. 27:1063-1066
A 50-year-old woman was admitted for active rheumatoid arthritis (RA). She was found to have RA 1 year prior to this admission. Past history was unremarkable and she had no family history for rheumatic diseases. As nonsteroidal anti-inflammatory drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f9dd1c0279c8404ed04bcd0db73ba05
https://doi.org/10.1007/s10067-008-0885-1
https://doi.org/10.1007/s10067-008-0885-1
Autor:
Junichi Yoshi, Kosuke Kaji, Hitoshi Yoshiji, Tadashi Namisaki, Hiroshi Fukui, Koji Yanase, Masaharu Yamazaki, Mitsuteru Kitade, Ryuichi Noguchi, Takemi Akahane, Masahito Uemura, Yasuhide Ikenaka, Tatsuhiro Tsujimoto
Publikováno v:
International Journal of Oncology. 32(1):193-199
Interferon (IFN) is known as a multifunctional cytokine. The aim of this study was to examine the different effects of IFN subclass; namely, IFN-alpha and IFN-beta, on hepatocellular carcinoma (HCC) growth especially in conjunction with angiogenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651d545d9b4d60c59124b1424d39993f
http://hdl.handle.net/10564/2321
http://hdl.handle.net/10564/2321